108 related articles for article (PubMed ID: 23639286)
1. The expression level of myocardial β1-adrenergic receptor affects metoprolol antihypertensive effects: a novel mechanism for interindividual difference.
Liu H; Xing X; Huang L; Huang Z; Yuan H
Med Hypotheses; 2013 Jul; 81(1):71-2. PubMed ID: 23639286
[TBL] [Abstract][Full Text] [Related]
2. Methylation of adrenergic β1 receptor is a potential epigenetic mechanism controlling antihypertensive response to metoprolol.
Jiang Q; Yuan H; Xing X; Liu J; Huang Z; Du X
Indian J Biochem Biophys; 2011 Oct; 48(5):301-7. PubMed ID: 22165287
[TBL] [Abstract][Full Text] [Related]
3. The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.
Chen L; Xiao T; Chen L; Xie S; Deng M; Wu D
Am J Med Sci; 2018 Mar; 355(3):235-239. PubMed ID: 29549925
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of the β1 adrenergic receptor in the myocardium results in insensitivity to metoprolol and reduces blood pressure in spontaneously hypertensive rats.
Huang Y; Liu XL; Wen J; Huang LH; Lu Y; Miao RJ; Liu X; Li Y; Xing XW; Yuan H
Mol Med Rep; 2017 Feb; 15(2):703-711. PubMed ID: 28000860
[TBL] [Abstract][Full Text] [Related]
5. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
[TBL] [Abstract][Full Text] [Related]
6. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.
Yuan H; Huang Z; Yang G; Lv H; Sang H; Yao Y
J Int Med Res; 2008; 36(6):1354-62. PubMed ID: 19094446
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
Zateyshchikov DA; Minushkina LO; Brovkin AN; Savel'eva EG; Zateyshchikova AA; Manchaeva BB; Nikitin AG; Sidorenko BA; Nosikov VV
Fundam Clin Pharmacol; 2007 Aug; 21(4):437-43. PubMed ID: 17635183
[TBL] [Abstract][Full Text] [Related]
9. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
[TBL] [Abstract][Full Text] [Related]
10. Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia.
Arnold AS; Tang YL; Qian K; Shen L; Valencia V; Phillips MI; Zhang YC
J Hypertens; 2007 Jan; 25(1):197-205. PubMed ID: 17143192
[TBL] [Abstract][Full Text] [Related]
11. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
14. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
[TBL] [Abstract][Full Text] [Related]
16. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment.
Suonsyrjä T; Donner K; Hannila-Handelberg T; Fodstad H; Kontula K; Hiltunen TP
Pharmacogenet Genomics; 2010 May; 20(5):342-5. PubMed ID: 20300048
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
18. Effect of the Arg389Gly β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Hjelvang BR; Henriksen T; Frandsen E; Forman JL; Torp-Pedersen C; Køber L; Poulsen HE
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):779-85. PubMed ID: 22703382
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population.
Mahesh Kumar KN; Ramu P; Rajan S; Shewade DG; Balachander J; Adithan C
J Cardiovasc Pharmacol; 2008 Nov; 52(5):459-66. PubMed ID: 19033826
[TBL] [Abstract][Full Text] [Related]
20. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
